<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epstein-Barr virus (EBV)-associated Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>) and nasopharyngeal <z:mp ids='MP_0002038'>carcinoma</z:mp> (NPC) usually occur in patients without clinically manifest deficiencies in anti-<z:mp ids='MP_0001799'>viral</z:mp> immunity </plain></SENT>
<SENT sid="1" pm="."><plain>In spite of expressing <z:mp ids='MP_0001799'>viral</z:mp> proteins, both <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> are apparently able to escape EBV-specific immunity in vivo </plain></SENT>
<SENT sid="2" pm="."><plain>EBI3 is an EBV-induced cytokine homologous to the interleukin (IL)-12 p40 subunit and can heterodimerize with IL-12 p35 </plain></SENT>
<SENT sid="3" pm="."><plain>It has been suggested that EBI3 may function to antagonize IL-12 and to inhibit the development of a Th1 immune response </plain></SENT>
<SENT sid="4" pm="."><plain>EBI3 expression has been studied in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> entities frequently associated with <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> to examine if EBI3 might contribute to local modulation of the immune response </plain></SENT>
<SENT sid="5" pm="."><plain>It is shown that EBI3 is strongly expressed in Hodgkin and Reed-Sternberg cells in 32 of 33 HL cases, independently of the EBV status of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, EBI3 expression was detected in the <z:e sem="disease" ids="C0205853" disease_type="Neoplastic Process" abbrv="">epithelial tumour</z:e> cells of six of 40 NPC biopsies but not in Burkitt <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>The results suggest that EBI3 may be an additional component of the repertoire employed by Hodgkin and Reed-Sternberg cells to inhibit an effective anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> or anti-<z:mp ids='MP_0001799'>viral</z:mp> immune response </plain></SENT>
</text></document>